These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24908142)

  • 1. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations.
    Gurzu S; Jung I
    Pathol Res Pract; 2012 Mar; 208(3):163-6. PubMed ID: 22361037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
    Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
    Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
    Tot T
    Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
    Saad RS; Silverman JF; Khalifa MA; Rowsell C
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability.
    McGregor DK; Wu TT; Rashid A; Luthra R; Hamilton SR
    Am J Surg Pathol; 2004 Jun; 28(6):712-8. PubMed ID: 15166663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition.
    Gurzu S; Szentirmay Z; Toth E; Bara T; Bara T; Jung I
    PLoS One; 2013; 8(3):e57699. PubMed ID: 23469219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
    Bayrak R; Haltas H; Yenidunya S
    Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of CK20, CK7, and CDX2 in colorectal carcinoma in correlation with pathomorphological characteristics.
    Ilieva N; Tashkova D; Staykov D; Serteva D; Feodorova Y; Mehterov N; Mollova A; Bachurska S
    Folia Med (Plovdiv); 2022 Apr; 64(2):214-220. PubMed ID: 35851772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability.
    Lanza G; Gafà R; Maestri I; Santini A; Matteuzzi M; Cavazzini L
    Mod Pathol; 2002 Jul; 15(7):741-9. PubMed ID: 12118112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
    Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
    Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.